Stamford, US Aug 22, 2025 (Issuewire.com) - Harrison Global Holdings Inc., formerly BloomZ Inc., has signed a strategic international partnership with Biotree Co., Ltd., a Korean biotech pioneer developing the world’s first natural product-based drug for metabolic syndrome.
Why This Matters to Investors
- Biotree’s PH-100 has completed Phase 1 trials in the U.S. and Phase 2A trials in Korea, showing strong results in reducing inflammation and improving cardiovascular health.
- The drug is expected to receive conditional approval by mid-2026, opening up prescription-only revenue streams.
- Biotree is the first Korean firm to extract Seapolynol from Gamtae seaweed—used in health foods, cosmetics, and pharmaceuticals.
- Harrison Global will help expand Biotree’s reach into the U.S., Japan, China, and broader Asia through joint ventures, licensing, and localized development.
Strategic Synergy
This partnership blends Harrison’s entertainment and youth engagement expertise with Biotree’s biotech innovation, creating a hybrid growth engine across lifestyle, wellness, and media sectors.
Executive Insight
"We’re thrilled to contribute to global health by supporting Biotree’s breakthrough treatment," said Ryoshin Nakade, Co-CEO of Harrison Global. "This partnership reflects our commitment to innovation and international expansion."
Enrique Vargas
Vargasfinancialinc@gmail.com
(845) 288-0020
Media Contact
Vargas Financial Inc Vargasfinancialinc@gmail.com (845) 288-0020
